Ascendis Pharma has entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan.

Ascendis will receive an upfront payment of $70 million, with additional development and regulatory milestones of up to $175 million, transfer pricing and commercial milestones. Ascendis Pharma is also eligible to receive royalties on sales in Japan.

“We are pleased to partner with Teijin Pharma given their track record of navigating regulatory approval and commercialization of rare disease and endocrinology product candidates in Japan, and commitment to providing best-in-class therapies,” said Jan Mikkelsen, Ascendis Pharma’s President, and CEO. “We believe this collaboration is a major step in our journey to achieve global reach for our current endocrinology rare disease portfolio by helping to address unmet medical needs of patients in Japan.”

Akimoto Uchikawa, Teijin Limited’s President, and CEO said, “Ascendis has leveraged its innovative TransCon technology platform to create a suite of highly differentiated product candidates with best-in-class potential that complement our existing pharmaceutical portfolio. We expect this partnership will contribute a great deal to advance our healthcare business vision to address issues of patients, families, and communities in need of more support followed by the introduction of pharmaceuticals in rare and intractable disease areas utilizing our business platform cultivated so far.”